Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · ENT

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 3 · 37.5%Low 3 · 37.5%Moderate 1 · 12.5%High 0 · 0%

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Moderate

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Disease severity, as measured by validated, patient‐reported symptom score · patients with chronic rhinosinusitis with nasal polyps

The review found no eligible studies for this question.

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Serious adverse events · patients with chronic rhinosinusitis with nasal polyps

It is very uncertain whether anti‐IgE mAb (omalizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.32 [0.05, 2]
5 studies · 329 participants
Very low

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an improvement in SNOT‐22 score of ≥ 8.9 points · patients with chronic rhinosinusitis with nasal polyps

Anti‐IgE mAb (omalizumab) may leads to higher avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an… compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 5.6 [1.99, 15.76]
2 studies · 265 participants
Low

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Extent of disease ‐ endoscopic score · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 312 participants
Low

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Extent of disease ‐ CT scan (lower score = better) · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 47 participants
Very low

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 38 participants
Very low

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Adverse events ‐ nasopharyngitis, including sore throat · patients with chronic rhinosinusitis with nasal polyps

Anti‐IgE mAb (omalizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.71 [0.29, 1.73]
5 studies · 329 participants
Low